Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vytorin Continues To Grow Globally As Schering Seeks Ways To ENHANCE U.S. Sales

This article was originally published in The Pink Sheet Daily

Executive Summary

Cholesterol franchise is up 6 percent overall as Zetia and Vytorin prescription sales drop 5 percent in the U.S. in the wake of negative trial results.

You may also be interested in...

Merck Revises Guidance To Include $700 Million Less In Vytorin/Zetia Sales

Company, however, reaffirms EPS guidance for the year.

FDA’s Change Of Heart On Vytorin Ads

Although the campaign had been running for years with no problems, FDA instructed Merck/Schering-Plough to revise the Vytorin DTC ads even as the agency publicly affirmed the utility of the drug.

FDA Postpones PDUFA Date For Schering-Plough’s Bridion To Third Quarter

Agency requires more time to analyze hypersensitivity study, firm says.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts